Drug Trial Radar · NCT05438420
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 12, 2023
Primary completion
Dec 30, 2027
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- Qurient Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 30, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
Conditions
- Esophageal Cancer
- Gastric Cancer
- Hepatocellular Cancer
- Cervical Cancer
Interventions
Q702Drug
The study drug Q702 will be administered once daily by mouth on Days 1 through 7, Days 15 through 21 and Days 29 through 35 of every treatment cycle.
PembrolizumabBiological
Pembrolizumab will be administered using IV infusion on Day 1 of each 3-week treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAETime frame: Up to approximately 2 years (Each Cycle is 42 Days)
- Tumor response using RECIST version 1.1 throughout studyTime frame: Up to approximately 2 years (Each Cycle is 42 Days)
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California
Norton Cancer Institute
Louisville, Kentucky
CHA Bundang Medical Center
Seongnam-si, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.